Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Sathyamangla V. Naga Prasad, PhD, was born in Chennai, India. He finished his PhD in molecular genetics at the School of Life Sciences, New Delhi, India. After his fellowship training, he joined the Division of Cardiology, Duke University Medical Center, as Assistant Research Professor. He joined the Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, as Assistant Staff in 2005. He is also Assistant Professor in the Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University.
Dr. Prasad has established a rigorous research program in the Department of Molecular Cardiology to identify novel signaling mechanisms regulating beta-adrenergic receptor function. Beta-adrenergic receptors are one of the strongest regulators of cardiac function, and their function is significantly compromised as the heart progresses towards cardiac dysfunction and failure. Therefore, understanding the underlying molecular mechanisms could potentially lead to novel therapeutic strategies. Dr. Prasad’s work has been published in many high-impact, peer-reviewed journals, and work from his lab is also presented at national meetings. Work in Dr. Prasad's lab is currently supported by grants from the American Heart Association.
Dr. Prasad is the recipient of the prestigious Louis N. and Arnold M. Katz Award for Young Investigators from the American Heart Association. He was a finalist for the Outstanding Early Career Investigator Award from the Council of Basic Cardiovascular Sciences of the American Heart Association. He also served as a Young Investigator Representative on the Leadership Committee of the Council of Basic Cardiovascular Sciences of the American Heart Association. He was selected as a member of the American Society of Pharmacology and Experimental Therapeutics.
novel paradigms in beta-adrenergic receptors signaling in heart failure
Awards & Honors
Loius M. and Arnold M. Katz Basic Research Award for Young Investigators, American Heart Association
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 2/28/2016, Dr. Prasad has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.